BriaCell Therapeutics Announces Pricing of Public Offering

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) has announced the pricing of its underwritten public offering, raising $5.55 million through the sale of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warrants have an exercise price of $0.9375 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. ThinkEquity acted as the sole book-running manager for the offering.

The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Its lead candidate, Bria-IMT™, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient's immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer.



BriaCell's public offering comes at a time when the biotechnology and healthcare sectors are facing challenging market conditions and investor sentiment. The global economic slowdown and geopolitical tensions have led to increased market volatility, making investors more risk-averse and cautious about allocating capital to biotechnology and healthcare companies. Additionally, the competition in the immunotherapy space and the uncertainty surrounding clinical trial results and regulatory approvals contribute to the cautious investor sentiment.

Despite these challenges, BriaCell's public offering reflects the Company's commitment to advancing its clinical pipeline and maintaining its operational capabilities. The funds raised from the offering will support the Company's working capital requirements, general corporate purposes, and the advancement of its business objectives. By doing so, BriaCell aims to enhance its competitive position, increase its revenue streams, and create long-term value for shareholders.



In conclusion, BriaCell Therapeutics' announcement of the pricing of its public offering highlights the Company's commitment to advancing its clinical pipeline and maintaining its operational capabilities. Despite the challenging market conditions and investor sentiment, BriaCell's public offering reflects the Company's long-term strategic goals and its determination to create value for shareholders. As the Company continues to advance its lead candidate, Bria-IMT™, and explore new opportunities in the biotechnology and healthcare sectors, investors should closely monitor BriaCell's progress and consider the potential benefits and risks associated with investing in the Company.